Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01683695 · ClinicalTrials.gov registry record · Phase 1
Safety Study of AMG 557 in Subjects With Lupus Arthritis
A Phase 1 study of Lupus Arthritis, Systemic Lupus Erythematosus, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 13
- Study locations
NCT01683695: Completed Phase 1 study of Lupus Arthritis, Systemic Lupus Erythematosus, sponsored by Amgen.
NCT01683695 is a Phase 1 study of Lupus Arthritis, Systemic Lupus Erythematosus that has completed, run by Amgen. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). The trial reports 13 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01683695, a Phase 1 study of Lupus Arthritis, Systemic Lupus Erythematosus, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, parallel, placebo-controlled, multiple dose study that will enroll approximately 40 systemic lupus erythematosus subjects with active lupus arthritis.
Conditions Studied
Interventions
- DRUG Matching Placebo
- DRUG AMG 557
Study Locations (13)
Other
- Research Site - Odense
- Research Site - Lille
- Research Site - Berlin
- Research Site - Taipei
- Research Site - Birmingham
- Research Site - London
California
- Research Site - Los Angeles
- Research Site - San Leandro
Connecticut
- Research Site - Danbury
New York
- Research Site - Manhasset
New South Wales
- Research Site - St Leonards
Kuala Lumpur
- Research Site - Kuala Lumpur
Sarawak
- Research Site - Kuching
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-06 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
What the finished NCT01683695 record still lists
NCT01683695 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Lupus Arthritis, Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Matching Placebo is the first listed.
NCT01683695 lists 13 locations in 7 states (Other, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT01683695 about?
NCT01683695 is a clinical study titled "Safety Study of AMG 557 in Subjects With Lupus Arthritis". This is a multicenter, randomized, double-blind, parallel, placebo-controlled, multiple dose study that will enroll approximately 40 systemic lupus erythematosus subjects with active lupus arthritis.
What is the current status of trial NCT01683695?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2012-06. Estimated completion is 2016-03.
What conditions does trial NCT01683695 study?
This clinical trial studies the following conditions: Lupus Arthritis, Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT01683695?
The interventions under investigation include: Matching Placebo (DRUG), AMG 557 (DRUG).
Who is sponsoring clinical trial NCT01683695?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01683695 being conducted?
This trial has 13 study locations across California, Connecticut, New York, New South Wales, Kuala Lumpur. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01683695's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia